High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi

High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi

Abstract Plasma Epstein‐Barr virus (EBV) DNA measurement has established prognostic utility in EBV‐driven lymphomas, where it serves as a circulating tumor DNA marker. The value of plasma EBV measurement may be amplified in sub‐Saharan Africa (SSA), where advanced imaging and molecular technologies...

Full description

Saved in:
Bibliographic Details
Main Authors: Nathan D. Montgomery, Cara Randall, Matthew Painschab, Ryan Seguin, Bongani Kaimila, Edwards Kasonkanji, Takondwa Zuze, Robert Krysiak, Marcia K. Sanders, Avian Elliott, Melissa B. Miller, Coxcilly Kampani, Fred Chimzimu, Maurice Mulenga, Blossom Damania, Tamiwe Tomoka, Yuri Fedoriw, Dirk P. Dittmer, Satish Gopal
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Cancer Medicine
Subjects:
diffuse large B‐cell lymphoma
Epstein‐Barr virus
HIV
prognosis
sub‐Saharan Africa
Online Access:https://doi.org/10.1002/cam4.2710
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Plasma Epstein‐Barr virus (EBV) DNA measurement has established prognostic utility in EBV‐driven lymphomas, where it serves as a circulating tumor DNA marker. The value of plasma EBV measurement may be amplified in sub‐Saharan Africa (SSA), where advanced imaging and molecular technologies for risk stratification are not typically available. However, its utility in diffuse large B‐cell lymphoma (DLBCL) is less certain, given that only a subset of DLBCLs are EBV‐positive. To explore this possibility, we measured plasma EBV DNA at diagnosis in a cohort of patients with DLBCL in Malawi. High plasma EBV DNA at diagnosis (≥3.0 log10 copies/mL) was associated with decreased overall survival (OS) (P = .048). When stratified by HIV status, the prognostic utility of baseline plasma EBV DNA level was restricted to HIV‐positive patients. Unexpectedly, most HIV‐positive patients with high plasma EBV DNA at diagnosis had EBV‐negative lymphomas, as confirmed by multiple methods. Even in these HIV‐positive patients with EBV‐negative DLBCL, high plasma EBV DNA remained associated with shorter OS (P = .014). These results suggest that EBV reactivation in nontumor cells is a poor prognostic finding even in HIV‐positive patients with convincingly EBV‐negative DLBCL, extending the potential utility of EBV measurement as a valuable and implementable prognostic marker in SSA.
ISSN:2045-7634

Similar Items